Key factors
sym | CAPR |
exch | US |
MCap | 159.09M |
Beta | 4.04 |
EPS | -0.83 |
Div date | 0000-00-00 |
Yesterday
sym | CAPR |
exch | US |
close | 4.82 |
50 Day MA | 5.448 |
200 Day MA | 4.689 |
52 Week High | 8.221 |
52 Week Low | 2.68 |
Target Price | 21.0 |
Market Cap Mln | 159.09 |
Share statistics
Shares Outstanding | 31.50M |
Shares Float | 26.04M |
Percent Institutions | 21.61 |
PercentInsiders | 8.197 |
SharesShort | 3501.73K |
Short Ratio | 8.74 |
Shares Short Prior Month | 3230.7K |
Short Percent | 13.40 |
Income
Revenue TTM | 25.17M |
Revenue Per Share TTM | 0.94 |
Quarterly Revenue Growth YOY | 1159.30 |
Gross Profit TTM | 1746.38K |
EBITDA | -23.0M |
Diluted Eps TTM | -0.83 |
earning
Operating Margin TTM | -0.10 |
EPS Estimate Current Quarter | -0.09 |
EPS Estimate Current Year | -0.96 |
EPS Estimate Next Quarter | -0.3 |
EPS Estimate Next Year | 0.1 |
Earnings Share | -0.83 |
Dividend
Dividend Date | 2019-06-05 |
Last Split Date | 2019-06-05 |
Last Split Factor | 1:10 |
business
Enterprise Value Ebitda | -6.93 |
Enterprise Value Revenue | 6.340 |
Book Value /share | 0.726 |
Price Book MRQ | 8.711 |
Price Sales TTM | 7.820 |
ProfitMargin | -0.88 |
ReturnOnAssetsTTM | -0.27 |
ReturnOnEquityTTM | -1.29 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Biotechnology |
Gic Sector | Health Care |
Gic Sub Industry | Biotechnology |
Industry | Biotechnology |
Sector | Healthcare |
Codes
ISIN | US14070B3096 |
CIK | 1133869 |
Code | CAPR |
CUSIP | 14070B309 |
Employer Id Number | 88-0363465 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2024-04-19 |
Home Category | Domestic |
info
Fiscal Year End | December |
Full Time Employees | 101.0 |
IPODate | 2007-02-13 |
International Domestic | Domestic |
MostRecent Quarter | 2023-12-31 |
Contact
Name | Capricor Therapeutics Inc |
Address | 10865 Road to the Cure, San Diego, CA, United States, 92121 |
Country Name | USA |
Phone | 858 727 1755 |
Web URL | https://www.capricor.com |
Logo URL | /img/logos/US/CAPR.png |
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases. In addition, the company develops CAP-2003, under pre-clinical development for the treatment of trauma related injuries and conditions. It has collaboration and distribution agreement with Nippon Shinyaku Co. Ltd., collaboration agreement with National Institute of Allergy and Infectious Diseases, license agreements with the Johns Hopkins University and Cedars-Sinai Medical Center, as well as cell line license agreement with Life Technologies Corporation. The company was founded in 2005 and is headquartered in San Diego, California.